Literature DB >> 12124178

p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy.

Vinay Tergaonkar1, Matthew Pando, Omid Vafa, Geoffrey Wahl, Inder Verma.   

Abstract

Chemotherapeutic agents simultaneously induce transcription factors p53 and NFkappaB. p53 induction can activate an apoptotic program, and resistance to chemotherapy correlates with the loss of a functional p53 pathway. By contrast, NFkappaB prevents apoptosis in response to chemotherapeutic agents. We have analyzed the p53 response in IKK1/2(-/-) MEFs, which lack detectable NFkappaB activity. Compared to WT fibroblasts, IKK1/2(-/-) fibroblasts showed increased cell death and p53 induction in response to the chemotherapeutic agent, doxorubicin. Reconstitution of IKK2, but not IKK1, increased Mdm2 levels and decreased doxorubicin-induced p53 stabilization and cell death. IKK2-mediated effects required its kinase function and were abrogated by coexpression of the dominant negative IkappaBalphaM, implying a role for NFkappaB in blocking chemotherapy-induced p53 and cell death.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124178     DOI: 10.1016/s1535-6108(02)00068-5

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  113 in total

1.  NF-kappaB inhibits T-cell activation-induced, p73-dependent cell death by induction of MDM2.

Authors:  Valere Busuttil; Nathalie Droin; Laura McCormick; Francesca Bernassola; Eleonora Candi; Gerry Melino; Douglas R Green
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

2.  Conditional ablation of Ikkb inhibits melanoma tumor development in mice.

Authors:  Jinming Yang; Ryan Splittgerber; Fiona E Yull; Sara Kantrow; Gregory D Ayers; Michael Karin; Ann Richmond
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

3.  CRE recombinase-inducible RNA interference mediated by lentiviral vectors.

Authors:  Gustavo Tiscornia; Vinay Tergaonkar; Francesco Galimi; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-30       Impact factor: 11.205

Review 4.  Nuclear factor (NF)-kappaB proteins: therapeutic targets.

Authors:  I M Verma
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

5.  Expression of the Bcl-3 proto-oncogene suppresses p53 activation.

Authors:  David Kashatus; Patricia Cogswell; Albert S Baldwin
Journal:  Genes Dev       Date:  2005-12-29       Impact factor: 11.361

6.  cIAP2 represses IKKα/β-mediated activation of MDM2 to prevent p53 degradation.

Authors:  Rosanna Lau; Min Ying Niu; M A Christine Pratt
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

7.  Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation.

Authors:  Yinghui Li; Qi-Ling Zhou; Wenjie Sun; Prashant Chandrasekharan; Hui Shan Cheng; Zhe Ying; Manikandan Lakshmanan; Anandhkumar Raju; Daniel G Tenen; Shi-Yuan Cheng; Kai-Hsiang Chuang; Jun Li; Shyam Prabhakar; Mengfeng Li; Vinay Tergaonkar
Journal:  Nat Cell Biol       Date:  2015-09-21       Impact factor: 28.824

Review 8.  The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy.

Authors:  Yong Lin; Lang Bai; Wenjie Chen; Shanling Xu
Journal:  Expert Opin Ther Targets       Date:  2010-01       Impact factor: 6.902

Review 9.  Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer.

Authors:  Sergei I Grivennikov; Michael Karin
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-16       Impact factor: 7.638

10.  The IKK complex contributes to the induction of autophagy.

Authors:  Alfredo Criollo; Laura Senovilla; Hélène Authier; Maria Chiara Maiuri; Eugenia Morselli; Ilio Vitale; Oliver Kepp; Ezgi Tasdemir; Lorenzo Galluzzi; Shensi Shen; Maximilien Tailler; Nicolas Delahaye; Antoine Tesniere; Daniela De Stefano; Aména Ben Younes; Francis Harper; Gérard Pierron; Sergio Lavandero; Laurence Zitvogel; Alain Israel; Véronique Baud; Guido Kroemer
Journal:  EMBO J       Date:  2009-12-03       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.